Akebia Therapeutics, Inc. (AKBA) Files Form 4 Insider Selling : Nicole R. Hadas Sells 1,557 Shares

Akebia Therapeutics, Inc. (AKBA): Nicole R. Hadas , SVP, General Counsel, Sec. of Akebia Therapeutics, Inc. sold 1,557 shares on Jul 5, 2016. The Insider selling transaction was reported by the company on Jul 6, 2016 to the Securities and Exchange Commission. The shares were sold at $7.47 per share for a total value of $11,625.34 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on Apr 5, 2016, Nicole R. Hadas (SVP, General Counsel, Sec.) sold 1,556 shares at $9.41 per share price.On Apr 5, 2016, Michel Dahan (SVP, Chief Business Officer) sold 1,401 shares at $9.41 per share price.Also, On Oct 5, 2015, Duane Nash (director) sold 996 shares at $8.65 per share price.On Apr 22, 2015, Muneer A Satter (director) purchased 420,000 shares at $8.25 per share price.

Shares of Akebia Therapeutics Inc (AKBA) ended Tuesday, Jul 6, 2016 session in red amid volatile trading. The shares closed down -0.13 points or -1.70% at $7.5 with 2,15,941 shares getting traded. Post opening the session at $7.55, the shares hit an intraday low of $7.36 and an intraday high of $7.8499 and the price vacillated in this range throughout the day. The company has a market cap of $285 M and the number of outstanding shares has been calculated to be 3,79,76,705 shares. The 52-week high of Akebia Therapeutics Inc is $14.2 and the 52-week low is $5.91.

Akebia Therapeutics Inc Money Flow Index Chart

Akebia Therapeutics Inc. is a biopharmaceutical company. The Company is focused on the development of therapeutics based on hypoxia inducible factor (HIF) biology and the commercialization of these products for patients with kidney disease. The Company’s lead product candidate AKB-6548 is being developed as a once-daily oral therapy. It has completed a Phase IIb study demonstrating that AKB-6548 can raise hemoglobin levels in non-dialysis patients with anemia related to chronic kidney disease (CKD). The Company is also conducting a Phase II study for the treatment of anemia in patients undergoing dialysis. The Company’s preclinical candidate AKB-6899 is a small molecule with minor structural differences from its lead compound AKB-6548. AKB-6899 is being developed for the treatment of certain cancers.

Leave a Reply

Akebia Therapeutics Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Akebia Therapeutics Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.